{
  "source": "PA-Notification-Lenvima.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1157-13\nProgram Prior Authorization/Notification\nMedication Lenvima® (lenvatinib)\nP&T Approval Date 4/2015, 4/2016, 7/2016, 7/2017, 7/2018, 11/2018, 11/2019, 11/2020,\n11/2021, 2/2022, 2/2023, 2/2024, 2/2025\nEffective Date 5/1/2025\n1. Background:\nLenvima (lenvatinib) is a kinase inhibitor indicated for the treatment of patients with locally\nrecurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer,\nin combination with Afinitor (everolimus), for the treatment of patients with advanced renal cell\ncarcinoma (RCC) following one prior anti-angiogenic therapy, in combination with Keytruda\n(pembrolizumab), for the first-line treatment of patients with advanced RCC, for the first-line\ntreatment of patients with unresectable hepatocellular carcinoma, and in combination with\npembrolizumab, for the treatment of patients with advanced endometrial carcinoma that is not\nmicrosatellite instability-high (MSI-H) or mismatch repair deficient (pMMR), who have disease\nprogression following prior systemic therapy in any setting and are not candidates for curative\nsurgery or radiation.\nIn addition, the National Cancer Comprehensive Network (NCCN) also recommends Lenvima for\nthe treatment of medullary thyroid carcinoma in patients who have experienced disease\nprogression while on Caprelsa (vandetanib) or Cometriq (cabozantinib), as a systemic therapy for\nrecurrent adenoid cystic carcinoma, and for the treatment of metastatic hepatocellular carcinoma,\nthymic carcinoma, and cutaneous melanoma.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of 19\nyears, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or under\nsome circumstances. Some states also mandate usage of other Compendium references. Where such\nma",
    "view.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or under\nsome circumstances. Some states also mandate usage of other Compendium references. Where such\nmandates apply, they supersede language in the benefit document or in the notification criteria.\n© 2025 UnitedHealthcare Services, Inc.\n1\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Lenvima will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Thyroid Cancer\n1. Initial Authorization\na. Lenvima will be approved based on all of the following criteria:\n(1) Diagnosis of differentiated thyroid cancer (DTC)\n-AND-\n(2) Disease is locally recurrent, metastatic, progressive, or symptomatic\n-AND-\n(3) Disease is radioactive iodine-refractory or ineligible\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Lenvima will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Lenvima\ntherapy\nAuthorization will be issued for 12 months.\nC. Renal Cell Cancer\n1. Initial Authorization\na. Lenvima will be approved based on all of the following criteria:\n(1) Diagnosis of advanced renal cell carcinoma\n-AND-\n(2) One of the following:\n© 2025 UnitedHealthcare Services, Inc.\n2\n(a) Both of the following:\ni. History of failure, contraindication, or intolerance to prior anti-\nangiogenic therapy [e.g., Avastin (bevacizumab), Votrient (pazopanib),\nSutent (sunitinib), Nexavar (sorafenib)].\n-AND-\nii. Used in combination with Afinitor (everolimus)\n-OR-\n(b) Used in combination with Keytruda (pembrolizumab)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Lenvima will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Lenvima\ntherapy\n-AND-\n(2) Used in combination with Afinitor (everolimus) or Keytruda (pembrolizumab)\nAuthorization will be issued for 12 months",
    "t does not show evidence of progressive disease while on Lenvima\ntherapy\n-AND-\n(2) Used in combination with Afinitor (everolimus) or Keytruda (pembrolizumab)\nAuthorization will be issued for 12 months.\nD. Hepatocellular Cancer\n1. Initial Authorization\na. Lenvima will be approved based on both of the following criteria:\n(1) Diagnosis of hepatocellular carcinoma\n-AND-\n(2) Disease is unresectable or metastatic\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Lenvima will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Lenvima\n© 2025 UnitedHealthcare Services, Inc.\n3\ntherapy\nAuthorization will be issued for 12 months.\nE. Endometrial Carcinoma\n1. Initial Authorization\na. Lenvima will be approved based on the following criterion:\n(1) Diagnosis of endometrial carcinoma\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Lenvima will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Lenvima\ntherapy\nAuthorization will be issued for 12 months.\nF. Adenoid Cystic Carcinoma\n1. Initial Authorization\na. Lenvima will be approved based on the following criteria:\n(1) Diagnosis of recurrent adenoid cystic carcinoma\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Lenvima will be approved based on the following criteria:\n(1) Patient does not show evidence of progressive disease while on Lenvima\ntherapy\nAuthorization will be issued for 12 months.\nG. Thymic Carcinoma\n1. Initial Authorization\na. Lenvima will be approved based on both the following criteria:\n(1) Diagnosis of thymic carcinoma\n© 2025 UnitedHealthcare Services, Inc.\n4\n-AND-\n(2) One of the following:\ni. Used as a single agent for those who cannot tolerate first-line combination\nregimens\nii. Used as a second line therapy in unresectable locally advanced disease,\nsolitary metastasis or ipsilateral pleural metastasis, or extrathoracic\nmetastatic disease\nAut",
    "rst-line combination\nregimens\nii. Used as a second line therapy in unresectable locally advanced disease,\nsolitary metastasis or ipsilateral pleural metastasis, or extrathoracic\nmetastatic disease\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Lenvima will be approved based on the following criteria:\n(1) Patient does not show evidence of progressive disease while on Lenvima\ntherapy\nAuthorization will be issued for 12 months.\nH. Cutaneous Melanoma\n1. Initial Authorization\na. Lenvima will be approved based on all of the following criteria:\n(1) Diagnosis of cutaneous melanoma\n-AND-\n(2) One of the following:\ni. Disease is unresectable\nii. Disease is metastatic\n-AND-\n(3) Used in combination with Keytruda (pembrolizumab)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Lenvima will be approved based on both of the following criteria:\n(1) Patient does not show evidence of progressive disease while on Lenvima\n© 2025 UnitedHealthcare Services, Inc.\n5\ntherapy\n-AND-\n(2) Used in combination with Keytruda (pembrolizumab)\nAuthorization will be issued for 12 months.\nI. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a\nCategory of Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Lenvima [package insert]. Woodcliff La",
    "r claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Lenvima [package insert]. Woodcliff Lake, NJ: Eisai Inc.; November 2024.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at NCCN\nDrugs and Biologics Compendium®. Accessed January 2, 2025.\nProgram Prior Authorization/Notification – Lenvima (lenvatinib)\nChange Control\n4/2015 New program.\n4/2016 Annual review. Added persistent locoregional and unresectable\nrecurrent disease to the thyroid cancer indication. Updated references.\n7/2016 Added coverage criteria for advanced renal cell cancer. Updated\nreferences.\n7/2017 Annual review. Updated background and criteria to include NCCN\nrecommended off label utilization for medullary thyroid carcinoma in\npatients with after Caprelsa or Cometriq. Updated formatting of criteria\nfor differentiated thyroid cancer to align with NCCN guidelines.\nUpdated references.\n© 2025 UnitedHealthcare Services, Inc.\n6\n7/2018 Annual review with no change to coverage criteria. Updated\nreferences.\n11/2018 Updated background and criteria to include new indication for\nunresectable hepatocellular carcinoma.\n11/2019 Annual review. Updated background and criteria to include new\nindication in combination with pembrolizumab for endometrial\ncarcinoma. Added general NCCN recommendations for use criteria.\nUpdated references.\n11/2020 Annual review. Updated background and criteria to include NCCN\nrecommended use for recurrent adenoid cystic carcinoma and anaplastic\nthyroid carcinoma. Added concurrent use with everolimus to the\nreauthorization criteria for renal cell cancer. Updated references.\n11/2021 Annual review. Updated background and criteria for new approval for\nuse in combination with Keytruda (pembrolizumab), for treatment\nadvanced RCC. Updated criteria per NCCN recommendations.\nRemoved anaplastic thyroid carcinoma criteria as it is no longer\nrecommended by NCCN. Updated",
    "tion with Keytruda (pembrolizumab), for treatment\nadvanced RCC. Updated criteria per NCCN recommendations.\nRemoved anaplastic thyroid carcinoma criteria as it is no longer\nrecommended by NCCN. Updated references.\n2/2022 Updated renal cell cancer reauthorization to include combination use of\nAfinitor (everolimus) or Keytruda (pembrolizumab).\n2/2023 Annual review. Updated references, added state mandate footnote.\nUpdated background and criteria to include NCCN recommended use\nfor cutaneous melanoma.\n2/2024 Annual review. Updated thyroid cancer criteria based on label and\nNCCN. Updated hepatobiliary and thymic cancer based on NCCN\nrecommendations. Updated references.\n2/2025 Annual review. Removed criteria for biliary cancer as it is no longer\nrecommended by NCCN. Removed combination use with Keytruda for\nendometrial cancer per NCCN. Updated background and references.\n© 2025 UnitedHealthcare Services, Inc.\n7"
  ]
}